News
-
Milestone Pharmaceuticals said that it has submitted an NDA for its etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) and that the FDA has conditionally approved the proposed trade name “Cardamyst.” The company… Read more . . .
-
Beckley Psytech has announced the initiation of a Phase 2b trial of BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin) in people with moderate-to-severe treatment resistant depression. In February 2023, the company announced that the FDA approved an IND… Read more . . .
-
Qnovia (formerly Respira Technologies) has announced a partnership with researchers at the University of Virginia (UVA) for the development of two new antimicrobial peptides for delivery via the company’s RespiRx vibrating mesh nebulizer technology. The… Read more . . .
-
According to Tiziana Life Sciences, the FDA is allowing patients with multiple sclerosis who are taking part in an expanded access program through Brigham and Women’s Hospital to use intranasal foralumab at home instead of… Read more . . .
-
Aculys Pharma says that it plans to move ahead with submission of a marketing application to Japanese authorities based on interim data showing that a Japanese Phase 3 clinical study of NRL-1 diazepam nasal spray… Read more . . .
-
Cyrano Therapeutics has announced the initiation of the Phase 2 FLAVOR trial of CYR-064 theophylline soft-mist nasal spray in patients who have lost their sense of smell following a viral infection. Cyrano announced plans for… Read more . . .
-
Startup Akita Biosciences, newly launched by faculty members of Brigham & Women’s Hospital to develop intranasal therapies, has announced the availability of its first nasal product. The company says that Profi prophylactic nasal spray is… Read more . . .
-
According to Ocugen, the US National Institute of Allergy and Infectious Diseases (NIAID) will conduct a study comparing the immune response generated by Ocugen’s OCU500 vaccine candidate delivered via inhalation versus OCU500 delivered as a… Read more . . .
-
Oragenics will acquire Odyssey Health’s breath-powered intranasal delivery device and dry powder nasal formulations, in a deal that includes 8 million shares of Oragenics Series F preferred stock and a total of $1 million in… Read more . . .
-
The annual Drug Delivery to the Lungs meeting returns to the Edinburgh International Conference Centre (EICC) December 6-8. DDL 2022 attracted a total of more than 1,000 delegates in person and online, and DDL 2023… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland